EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended...
SHA: 688235
BeiGene Rebrands to BeOne Medicines and Relocates to Switzerland
BeiGene (NASDAQ: ONC, HKG: 6160, SHA: 688235), a global oncology company, has officially rebranded to...
BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology company proposing to rename...
BeiGene Announces Plans to Relocate Headquarters to Switzerland from Cayman Islands
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology company that has proposed...
BeiGene’s Sonrotoclax Gains NMPA Priority Review for MCL Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
BeiGene Wins USPTO Ruling Invalidating Pharmacyclics’ Patent Claims
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
BeiGene’s Sonrotoclax NDA Accepted by NMPA for CLL/SLL Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China
The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...
BeiGene Halts Ociperlimab Clinical Program for Lung Cancer
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist formerly known as...
BeiGene’s Tevimbra Recommended for EU Approval in Small Cell Lung Cancer
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist proposing to rename...
BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...
BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from...
BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...
BeiGene’s Tevimbra Receives FDA Approval for HER2-Negative Gastric Cancer Treatment
China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that the...
BeiGene Rebrands to BeOne Medicines Ltd, Ticker Symbol Changes to “ONC”
China-based BeiGene Ltd, listed on Nasdaq (NASDAQ: BGNE, HKG: 6160, SHA: 688235), has announced a...
BeiGene Ltd Acquires Global Rights to CSPC’s MAT2A Inhibitor SYH2039
BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a significant licensing agreement...
Mabwell Bioscience Enters Licensing Agreement for Biosimilar Denosumab in Peru
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing agreement with its...
Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...
BeiGene’s Tevimbra Receives EC Approval for First-Line ESCC and G/GEJ Adenocarcinoma Treatments
China-based biotech company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has received a marketing...